{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:10:57Z","timestamp":1773436257828,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hereditary hemorrhagic telangiectasia (HHT; Rendu-Osler-Weber syndrome) affects the capillary and larger vessels, leading to arteriovenous shunts. Epistaxis is the main symptom impairing quality of life. The aim of the Osler Calendar is to offer information about the extent of the systemic disease and the current state of treatment. A care plan with information on the rare disease and self-treatment of epistaxis was created. Organ examinations and ongoing treatments were recorded. A questionnaire documents the treatment success, including patient satisfaction, frequency of hemorrhage and hemoglobin levels. The patients using the Osler Calendar for at least one year (n = 54) were surveyed. Eighty-five percent of patients (n = 46) used the calendar to gain information about HHT. Seventy-two percent (n = 39) used the Osler Calendar for instructions on the self-treatment of nosebleeds. The calendar increased patients\u2019 understanding for the need for organ screenings from 48% (n = 26) to 81% (n = 44). Seventy-nine percent (n = 43) of patients confirmed that the Osler Calendar documented their therapeutic process either well or very well. Fifty-two percent (n = 28) saw an improvement in the therapeutic process due to the documentation. The Osler Calendar records the individual intensity of the disease and facilitates the communication between attending physicians. It is a tool for specialists to review treatment strategies. Furthermore, the calendar enhances patients\u2019 comprehension of their condition.<\/jats:p>","DOI":"10.3390\/jcm10204720","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T22:42:18Z","timestamp":1634251338000},"page":"4720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hereditary Hemorrhagic Telangiectasia: Success of the Osler Calendar for Documentation of Treatment and Course of Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Caroline T.","family":"Seebauer","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4694-7219","authenticated-orcid":false,"given":"Viola","family":"Freigang","sequence":"additional","affiliation":[{"name":"Department of Trauma, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-0953","authenticated-orcid":false,"given":"Franziska E.","family":"Schwan","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bohr","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-1130","authenticated-orcid":false,"given":"Thomas S.","family":"K\u00fchnel","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia E. C.","family":"Andorfer","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Regensburg University Medical Center, Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.otc.2017.09.017","article-title":"Hereditary Hemorrhagic Telangiectasia","volume":"51","author":"Wirsching","year":"2018","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-018-0850-2","article-title":"European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)","volume":"13","author":"Shovlin","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.21053\/ceo.2016.00318","article-title":"Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View","volume":"10","author":"Wirsching","year":"2017","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2500\/105065899782102890","article-title":"A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia","volume":"13","author":"Lund","year":"1999","journal-title":"Am. J. Rhinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00405-016-4431-5","article-title":"Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT)","volume":"274","author":"Wirsching","year":"2017","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/lsm.23289","article-title":"Safety and Efficacy of Blue Light Laser Treatment in Hereditary Hemorrhagic Telangiectasia","volume":"53","author":"Bertlich","year":"2021","journal-title":"Lasers Surg. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","article-title":"A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia","volume":"269","author":"Rohrmeier","year":"2012","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1024\/0301-1526\/a000253","article-title":"Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)","volume":"42","author":"Chavan","year":"2013","journal-title":"Vasa"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","article-title":"The Young\u2019s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia","volume":"26","author":"Richer","year":"2012","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"H959","DOI":"10.1152\/ajpheart.01251.2009","article-title":"The physiological role of endoglin in the cardiovascular system","volume":"299","author":"Bernabeu","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bernabeu, C., Bayrak-Toydemir, P., McDonald, J., and Letarte, M. (2020). Potential Second-Hits in Hereditary Hemorrhagic Telangiectasia. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113571"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s00261-018-1671-4","article-title":"Liver involvement in hereditary hemorrhagic telangiectasia","volume":"43","author":"Buscarini","year":"2018","journal-title":"Abdom. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid\u2014A double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10103-017-2144-7","article-title":"Sinonasal quality of life outcomes following laser treatment of epistaxis related to hereditary hemorrhagic telangiectasia","volume":"32","author":"Kuan","year":"2017","journal-title":"Lasers Med. Sci."},{"key":"ref_17","first-page":"E10","article-title":"Hereditary hemorrhagic telangiectasia-laser treatment of epistaxis","volume":"96","author":"Poje","year":"2017","journal-title":"Ear. Nose Throat J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E689","DOI":"10.1002\/lary.28824","article-title":"In-Office KTP Laser for Treating Hereditary Hemorrhagic Telangiectasia\u2013Associated Epistaxis","volume":"131","author":"Wu","year":"2021","journal-title":"Laryngoscope"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.otc.2016.02.010","article-title":"Treatment of Hereditary Hemorrhagic Telangiectasia\u2013Related Epistaxis","volume":"49","author":"Sautter","year":"2016","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/138161206776361255","article-title":"Treatment of Recurrent Epistaxis in HHT","volume":"12","author":"Geisthoff","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00405-011-1677-9","article-title":"Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia","volume":"268","author":"Lange","year":"2011","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marcos, S., Botella, L.M., Albi\u00f1ana, V., Arbia, A., and de Rosales, A.M. (2021). Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173845"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1002\/ajh.24878","article-title":"Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia","volume":"92","author":"Chavan","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_24","first-page":"2045894018805406","article-title":"Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension","volume":"9","author":"Sommer","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Buscarini","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JOP.2014.001321","article-title":"American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning","volume":"10","author":"Mayer","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Von dem Knesebeck, O., Koens, S., Marx, G., and Scherer, M. (2019). Perceptions of time constraints among primary care physicians in Germany. BMC Fam. Pract., 20.","DOI":"10.1186\/s12875-019-1033-5"},{"key":"ref_28","unstructured":"(2021, August 16). My HHT Tracker App-CureHHT. Available online: https:\/\/curehht.org\/understanding-hht\/get-support\/my-hht-tracker-app\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4258\/hir.2018.24.3.207","article-title":"Effectiveness of Mobile Health Application Use to Improve Health Behavior Changes: A Systematic Review of Randomized Controlled Trials","volume":"24","author":"Han","year":"2018","journal-title":"Healthc. Inform. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"de Gussem, E.M., Kroon, S., Hosman, A.E., Kelder, J.C., Post, M.C., Snijder, R.J., and Mager, J.J. (2020). Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113581"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Majumdar, S., and McWilliams, J.P. (2020). Approach to Pulmonary Arteriovenous Malformations: A Comprehensive Update. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061927"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.echo.2014.12.008","article-title":"Clinical implications of pulmonary shunting on saline contrast echocardiography","volume":"28","author":"Velthuis","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_33","first-page":"231","article-title":"Nasal self-packing for epistaxis in Hereditary Hemorrhagic Telangiectasia increases quality of life","volume":"57","author":"Droege","year":"2019","journal-title":"Rhinology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:14:51Z","timestamp":1760166891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":33,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204720"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204720","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]}}}